Methods for treating cancer
AssigneeUCL Business PLC
InventorsHenning Walczak, Silvia Von Karstedt
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and materials for treating an individual with KRAS-mutated cancer or a cancer in which ROCK is inhibited independently of mutated KRAS. The invention is based on the prevention or disruption of the binding of TRAIL-Receptor to its ligand, TRAIL, in vivo, for example by use of an agent that neutralizes TRAIL and/or a the TRAIL-Receptor (such TRAIL-R2) and/or diminishes TRAIL/TRAIL-Receptor activity, thereby reducing cancer cell transformation, migration and metastasis, prolonging survival of patients.
Claims14
A method for treating an individual with a Kirsten rat sarcoma viral oncogene homologue (KRAS)-mutated cancer, or a cancer in which Rho Associated Coiled-Coil Containing Protein Kinase (ROCK) is inhibited independently of KRAS mutation, the method comprising administering to the individual a therapeutically-effective amount of an agent selected from the group consisting of:
- (i) an agent that binds to and neutralises TNF-related apoptosis-inducing ligand (TRAIL), and
- (ii) an agent that binds to and neutralises TRAIL-receptor 2 (TRAIL-R2).
Dependencies are inferred from the claim text.